AU2020350677A1 - Radiolabeling of anti-CD45 immunoglobulin and methods of use thereof - Google Patents

Radiolabeling of anti-CD45 immunoglobulin and methods of use thereof Download PDF

Info

Publication number
AU2020350677A1
AU2020350677A1 AU2020350677A AU2020350677A AU2020350677A1 AU 2020350677 A1 AU2020350677 A1 AU 2020350677A1 AU 2020350677 A AU2020350677 A AU 2020350677A AU 2020350677 A AU2020350677 A AU 2020350677A AU 2020350677 A1 AU2020350677 A1 AU 2020350677A1
Authority
AU
Australia
Prior art keywords
pci
antibody
subject
cells
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020350677A
Other languages
English (en)
Inventor
Dale Ludwig
Sandesh SETH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actinium Pharmaceuticals Inc
Original Assignee
Actinium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actinium Pharmaceuticals Inc filed Critical Actinium Pharmaceuticals Inc
Publication of AU2020350677A1 publication Critical patent/AU2020350677A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2020350677A 2019-09-17 2020-09-17 Radiolabeling of anti-CD45 immunoglobulin and methods of use thereof Pending AU2020350677A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962901290P 2019-09-17 2019-09-17
US62/901,290 2019-09-17
PCT/US2020/051324 WO2021055638A1 (en) 2019-09-17 2020-09-17 Radiolabeling of anti-cd45 immunoglobulin and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2020350677A1 true AU2020350677A1 (en) 2022-04-14

Family

ID=74883490

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020350677A Pending AU2020350677A1 (en) 2019-09-17 2020-09-17 Radiolabeling of anti-CD45 immunoglobulin and methods of use thereof

Country Status (7)

Country Link
US (1) US12605472B2 (https=)
EP (1) EP4031188A4 (https=)
JP (2) JP7826190B2 (https=)
CN (1) CN114728074A (https=)
AU (1) AU2020350677A1 (https=)
CA (1) CA3154732A1 (https=)
WO (1) WO2021055638A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023137335A2 (en) * 2022-01-11 2023-07-20 Actinium Pharmaceuticals, Inc. Methods for treating cd33-positive hematological malignancies
JP2025510189A (ja) 2022-03-24 2025-04-14 アクティニウム ファーマシューティカルズ インコーポレイテッド ヒト化抗ｃｄ４５抗体
WO2025064402A1 (en) * 2023-09-22 2025-03-27 St. Jude Children's Research Hospital, Inc. Method for treating sickle cell disease by targeting senescent cells
CN119842630B (zh) * 2024-12-31 2025-12-26 江苏为真生物医药技术股份有限公司 抗人cd45单克隆抗体杂交瘤细胞株及分泌抗体及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273738A (en) * 1990-03-03 1993-12-28 Fred Hutchinson Cancer Research Center Radiation delivery to lymphoid and marrow tissues
EP3297684B1 (en) * 2015-05-21 2020-12-23 Actinium Pharmaceuticals, Inc. Infusion administration of conjugated monoclonal antibodies
CN108026526B (zh) * 2015-06-09 2023-05-12 爱迪塔斯医药公司 用于改善移植的crispr/cas相关方法和组合物
AU2016274989A1 (en) 2015-06-12 2017-11-02 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
WO2017155937A1 (en) * 2016-03-07 2017-09-14 Actinium Pharmaceuticals, Inc. Stabilized radiolabeled anti-cd45 immunoglobulin compositions
WO2019084273A1 (en) * 2017-10-25 2019-05-02 Actinium Pharmaceuticals, Inc. METHODS OF ANTI-CD45-BASED LYMPHODEPPLICATION AND USES THEREOF IN COMBINATION WITH ACT-BASED ANTICANCER THERAPIES
US20230132400A9 (en) 2017-11-10 2023-04-27 Actinium Pharmaceuticals, Inc. Combination therapy for treatment of a hematological disease
WO2019136422A1 (en) * 2018-01-08 2019-07-11 Actinum Pharmaceuticals, Inc. Combination immunotherapy and chemotherapy for the treatment of a hematological malignancy
CA3137908A1 (en) 2019-04-25 2020-10-29 Actinium Pharmaceuticals, Inc. Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases

Also Published As

Publication number Publication date
US12605472B2 (en) 2026-04-21
WO2021055638A1 (en) 2021-03-25
EP4031188A1 (en) 2022-07-27
US20220378955A1 (en) 2022-12-01
CA3154732A1 (en) 2021-03-25
JP7826190B2 (ja) 2026-03-09
EP4031188A4 (en) 2023-11-01
CN114728074A (zh) 2022-07-08
JP2026047359A (ja) 2026-03-13
JP2022548694A (ja) 2022-11-21

Similar Documents

Publication Publication Date Title
US12605472B2 (en) Radiolabeling of anti-CD45 immunoglobulin and methods of use thereof
JP2022106807A (ja) Ｃｄ１１７＋細胞を枯渇させるための組成物及び方法
US7709000B2 (en) Antibody recognizing a small subset of human hematopoietic cells
ES2686692T3 (es) Anticuerpo monoclonal anti CD146
KR101893720B1 (ko) 방사 면역 접합체 및 그 용도
KR20190039085A (ko) 세포의 고갈을 위한 조성물 및 방법
JP2015501654A (ja) 治療用キメラ型抗ｃｄ３７抗体ｈｈ１
Chen et al. Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211–labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation
US11912780B2 (en) Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies
CN116940386A (zh) 吡咯并苯并二氮杂䓬-抗体缀合物以及其用途
JP2025126170A (ja) 悪性および非悪性血液疾患の治療のための免疫枯渇の組成物および方法
Malviya et al. Imaging T-lymphocytes in inflammatory diseases: a nuclear medicine approach.
JP2025143266A (ja) 悪性および非悪性血液疾患の治療のための免疫枯渇の組成物および方法
Graves et al. Developments and translational relevance for the canine haematopoietic cell transplantation preclinical model
KR20250161031A (ko) 조혈 전구세포 동원 방법
WO2011144744A1 (en) Targeted radioactive compound for human cd66 for the treatment of disorders
HK40028713A (en) Anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies
Waldmann et al. IL-2 Receptor-Directed Immunotherapy: A Model of Immune Intervention